Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Français (Suisse)
Italiano
Nederlands (Nederland)
Nederlands (België)
MARKETS
Equities
United States
North America
Europe
Asia
Middle East
More Equities
Indexes
S&P 500
DOW JONES
NASDAQ 100
EURO STOXX 50
NIKKEI 225
More Indexes
Currency / Forex
USD / EUR
USD / CAD
USD / MXN
USD / BRL
USD / INR
More Currencies
Commodities
GOLD
CRUDE OIL (WTI)
CRUDE OIL (BRENT)
SILVER
PLATINUM
More Commodities
Cryptocurrencies
BITCOIN
ETHEREUM
Trackers & ETF
Rankings and News
Advanced Search
NEWS
Latest News
Companies
Markets
Economy
Currency / Forex
Commodities
Interest Rates
Finance Pro.
Business Leaders
Cryptocurrencies
Cybersecurity
Economic Calendar
Listed companies
Analyst Reco.
Rumors
IPOs
Capital Markets Transactions
New Contracts
Profit Warnings
Appointments
Press Releases
Events
Security Transactions
Financial Calendar
Sector News
Energy
Basic Materials
Industrials
Consumer Cyclical
Consumer Non-Cyclical
Financials
Healthcare
Technology
Real Estate
Utilities
ANALYSIS
All Analysis
Must Read
Weekly market update
Stock Trading Strategies
STOCK PICKS
All Stock Picks
Subscribe
PORTFOLIOS
My Portfolio
Virtual Portfolios
MarketScreener Portfolios
USA Portfolio
European Portfolio
Asian Portfolio
WATCHLISTS
My Watchlists
Watchlists
My previous session
My most visited
Most popular
Investment Style
Undervalued stocks
Yield stocks
Growth stocks
Trend-Following Stocks
ESG stocks
Quality stocks
Investment Themes
Biotechnology
The Golden Age of Video Games
In Vino Veritas
Smart City
Sin stocks
Financial Data
RANKINGS
Top News
Most Read News
Hot News
Top Fundamentals
Top Capitalization
Top Yield
Top PER
Top Consensus
Top Fundamentals
Top ranking ESG
Top Technicals
Top RSI
Unusual volumes
Top Gaps
Top STIM
Breakouts
Trends
Top Movers
Top USA
Top Canada
Top U.K.
Top Germany
Top Europe
Top Asia
SCREENERS
Investment Themes
Smart City
In Vino Veritas
Water
Ageing Population
US Basketball
Financial Data
Technical Rankings
Oversold stocks
Overbought stocks
Close to resistance
Close to support
Accumulation Phases
Most volatile stocks
Fundamental Rankings
Top Investor Rating
Top Trading Rating
Top Consensus
Growth stocks
Yield stocks
Low valuations
Stock Screener Home
My Screeners
All my stocks
Watchlists
Virtual Portfolios
TOOLS
MarketScreener tools
Stock Screener
iPhone App
Expert tools
Stock Screener PRO
Portfolio Creator
Event Screener
Tools
Dynamic Chart
Financial Calendar
Economic Calendar
Sector Research
Currency Converter
ProRealTime Trading
OUR SERVICES
Our subscriptions
MarketScreener Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Our Stock Picks
Thematic Investment Lists
Stock Screener
Homepage
Equities
Netherlands
Euronext Amsterdam
Galapagos NV
News
Summary
GLPG
BE0003818359
GALAPAGOS NV
(GLPG)
Add to my list
Report
Real-time Euronext Amsterdam -
11:39 2022-08-08 am EDT
53.12
EUR
+0.04%
04:02p
Galapagos receives transparency notification from FMR LLC
GL
04:01p
Galapagos receives transparency notification from FMR LLC
AQ
08:02a
RBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
Summary
Quotes
Charts
News
Ratings
Calendar
Company
Financials
Consensus
Revisions
Summary
Most relevant
All News
Analyst Reco.
Other languages
Press Releases
Official Publications
Sector news
MarketScreener Strategies
Most relevant news about GALAPAGOS NV
04:02p
Galapagos receives transparency notification from FMR LLC
GL
04:01p
Galapagos receives transparency notification from FMR LLC
AQ
08:02a
RBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
08/05
Galapagos Q2 Loss Narrows as Net Revenue Falls
MT
08/05
TRANSCRIPT
: Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
CI
08/04
First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
08/04
Galapagos NV Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/15
Morgan Stanley Adjusts Galapagos' Price Target to $79 from $80, Keeps Overweight Rating
MT
06/23
GALAPAGOS
: to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
06/23
GALAPAGOS
: increases share capital through subscription right exercises - Form 6-K
PU
06/22
TRANSCRIPT
: Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call
CI
06/22
Pharmaceutical Group Galapagos Buys Cell Therapy Developers CellPoint, AboundBio For $2..
MT
06/21
Galapagos Expands Cell Therapy Capabilities Through Two Acquisitions
MT
06/21
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
GL
06/21
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
GL
More most relevant news
All news about GALAPAGOS NV
04:02p
Galapagos receives transparency notification from FMR LLC
GL
04:01p
Galapagos receives transparency notification from FMR LLC
AQ
08:02a
RBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
08/05
Galapagos Q2 Loss Narrows as Net Revenue Falls
MT
08/05
TRANSCRIPT
: Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
CI
08/04
First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
08/04
Galapagos NV Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/15
Morgan Stanley Adjusts Galapagos' Price Target to $79 from $80, Keeps Overweight Rating
MT
06/23
GALAPAGOS
: to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
06/23
GALAPAGOS
: increases share capital through subscription right exercises - Form 6-K
PU
More news
News in other languages on GALAPAGOS NV
04:17p
FMR groter in Galapagos
04:02p
Galapagos ontvangt transparantieverklaring van FMR LLC
04:02p
Galapagos ontvangt transparantieverklaring van FMR LLC
08/05
Galapagos réduit sa perte au 2e trimestre et réduit son revenu net
08/05
Sterk kwartaal voor Jyseleca van Galapagos
08/04
Galapagos verhoogt verwachte cashburn
08/04
Eerste belangrijke stappen in heropbouw van pijplijn en sterke commerciële vooruitgang ..
08/04
Eerste belangrijke stappen in heropbouw van pijplijn en sterke commerciële vooruitgang ..
08/04
Galapagos NV annonce ses résultats pour le semestre se terminant le 30 juin 2022
07/25
ACTUALIZACIÓN DE LAS FUERTES VARIACI
: La adquisición de Bobst, Eutelsat se sale de la órb..
More news
Analyst Recommendations on GALAPAGOS NV
08:02a
RBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
MT
07/15
Morgan Stanley Adjusts Galapagos' Price Target to $79 from $80, Keeps Overweight Rating
MT
05/09
RBC Raises Price Target on Galapagos to $62 From $60, Maintains Sector Perform Rating
MT
02/28
RBC Cuts Price Target on Galapagos to $60 From $63, Maintains Sector Perform Rating
MT
01/28
Bryan Garnier Double Upgrades Galapagos NV to Buy From Sell, Lowers PT to 65 Euros From..
MT
More recommendations
Press releases
04:02p
Galapagos receives transparency notification from FMR LLC
GL
04:01p
Galapagos receives transparency notification from FMR LLC
AQ
08/04
First key steps in pipeline rebuild and strong commercial progress in H1 2022
GL
06/23
GALAPAGOS
: to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
06/23
GALAPAGOS
: increases share capital through subscription right exercises - Form 6-K
PU
More press releases
Powered by Scoopnest.com
Official Publications
06/20
Share buyback
06/20
Share buyback
06/01
Crossing thresholds
06/01
Crossing thresholds
05/06
Press Release
05/05
1st quarter report
More Official Publications
Upcoming event on GALAPAGOS NV
09/08/22
Citi BioPharma Conference
Company calendar
Upcoming sector events
10/26/22
IQVIA HOLDINGS INC.
: Q3 2022 Earnings Release (Projected)
10/27/22
ALNYLAM PHARMACEUTICALS, INC.
: Q3 2022 Earnings Release (Projected)
10/27/22
SEAGEN INC.
: Q3 2022 Earnings Release (Projected)
11/03/22
MODERNA, INC.
: Q3 2022 Earnings Release (Projected)
More events
Sector
Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research
Slave